---
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew D'Mello, Editorial
    Director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew D'Mello, Editorial
    Director here at Emerge AI Resea
  name: Matthew D
  position: 53
- category: unknown
  confidence: medium
  context: the AI and Business Podcast. I'm Matthew D'Mello, Editorial Director here
    at Emerge AI Research. Today's guest is Scot
  name: Editorial Director
  position: 70
- category: unknown
  confidence: medium
  context: . I'm Matthew D'Mello, Editorial Director here at Emerge AI Research. Today's
    guest is Scott Bradley, Vice President o
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Scott Bradley, Vice President
    of AI and Innovation at Novartis.
  name: Scott Bradley
  position: 134
- category: unknown
  confidence: medium
  context: erge AI Research. Today's guest is Scott Bradley, Vice President of AI
    and Innovation at Novartis. Scott joins us
  name: Vice President
  position: 149
- category: unknown
  confidence: medium
  context: al series on AI and drug development sponsored by Intelligencia AI. And
    without further ado, here's our conversation
  name: Intelligencia AI
  position: 945
- category: unknown
  confidence: medium
  context: to get past the gut instinct. So many leaders in Farman Biotech have decades
    of experience, and they have pretty
  name: Farman Biotech
  position: 2435
- category: unknown
  confidence: medium
  context: ore indie films. No mystery to the folks at home. If I blurred my background,
    you'd see a wall of musica
  name: If I
  position: 8462
- category: unknown
  confidence: medium
  context: ased on what's also going on in the organization? But I think really what
    the change that we're seeing he
  name: But I
  position: 13283
- category: unknown
  confidence: medium
  context: ecutive thought leaders, everyone from the CIO of Goldman Sachs to the
    head of AI at Raytheon and AI pioneers lik
  name: Goldman Sachs
  position: 16417
- category: unknown
  confidence: medium
  context: o the head of AI at Raytheon and AI pioneers like Joshua Bengio. With nearly
    a million annual listeners, AI and B
  name: Joshua Bengio
  position: 16482
- category: unknown
  confidence: medium
  context: eve you can help other leaders move the needle on AI ROI, visit Emerge.com
    and fill out our thought leader
  name: AI ROI
  position: 16948
- category: media
  confidence: high
  context: The host's organization, where the podcast is produced.
  name: Emerge AI Research
  source: llm_enhanced
- category: pharmaceutical
  confidence: high
  context: The company where the guest, Scott Bradley, is the Vice President of AI
    and Innovation.
  name: Novartis
  source: llm_enhanced
- category: tech
  confidence: high
  context: The sponsor of the special series on AI and drug development.
  name: Intelligencia AI
  source: llm_enhanced
- category: pharmaceutical
  confidence: high
  context: Mentioned as having the head of AI who discussed similar changes happening
    in the entertainment space.
  name: Moderna
  source: llm_enhanced
- category: finance
  confidence: high
  context: Mentioned as an example of an organization whose CIO has been featured
    on the podcast.
  name: Goldman Sachs
  source: llm_enhanced
- category: technology/defense
  confidence: high
  context: Mentioned as an example of an organization whose head of AI has been featured
    on the podcast.
  name: Raytheon
  source: llm_enhanced
- category: media
  confidence: high
  context: The website where potential guests can apply to be on the podcast.
  name: Emerge.com
  source: llm_enhanced
- category: media
  confidence: high
  context: The podcast itself, which is a platform for discussing enterprise AI adoption.
  name: AI and Business Podcast
  source: llm_enhanced
date: 2025-05-22 06:00:00 +0000
duration: 19
has_transcript: false
insights:
- actionable: false
  confidence: medium
  extracted: pharma
  text: the future of pharma is to be able to continuously.
  type: prediction
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_5.22.25_-_Scott_Bradley.mp3?dest-id=151434
processing_date: 2025-10-05 15:50:27 +0000
quotes:
- length: 140
  relevance_score: 4
  text: Are you driving AI transformation at your organization or maybe you're guiding
    critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- impact_reason: This is a strong declaration that intuition is being replaced by
    data in high-stakes leadership decisions, signaling a major cultural shift required
    for AI adoption.
  relevance_score: 10
  source: llm_enhanced
  text: Anybody who's still going by their gut in the C-suite and leadership positions,
    those folks are out with their knives. We're getting rid of the gut, or at least
    it's going to have a much smaller opportunity space than it ever did before.
  topic: Business Strategy/Leadership
- impact_reason: Defines the core business model transformation occurring in Pharma,
    moving from mass production to niche, high-precision products.
  relevance_score: 10
  source: llm_enhanced
  text: We have moved beyond the era of the blockbuster drug. We are moving into the
    era... indie film drugs, right? They go see them at the art house. Much more narrowly
    focused, targeted, effective therapies for smaller patient populations.
  topic: Business Strategy/Trends
- impact_reason: 'Provides actionable strategic advice for technology implementation:
    integration decisions (buy/build, model type) are spectrums, not binary choices.'
  relevance_score: 10
  source: llm_enhanced
  text: Foundational models versus bespoke models. Well, it's a little bit more of
    a spectrum. Buy versus built. Well, no one's 100%. You know, it's not one or the
    other. I think that that's yet another spectrum rather than a binary that that
    we're going to see.
  topic: Technology Strategy
- impact_reason: Quantifies the revolutionary speed and complexity handling capability
    AI brings to core scientific research.
  relevance_score: 10
  source: llm_enhanced
  text: What's driving a lot of the excitement for AI in particular, in the drug development
    phase and the research phase is the ability to just understand the massive complexity
    of proteins and what used to take months of human effort to decode is now taking
    AI just minutes or hours.
  topic: Technology/R&D Efficiency
- impact_reason: A direct statement on the convergence of the pharmaceutical industry
    with the technology sector, signaling a major structural shift.
  relevance_score: 10
  source: llm_enhanced
  text: There's this multi continuum that exists in the future as you ask of what
    a pharma company looks like. It looks a lot more like a tech company.
  topic: Industry Trends/Business Strategy
- impact_reason: Directly links the future success of pharma to adopting agile methodologies
    common in software development.
  relevance_score: 10
  source: llm_enhanced
  text: The future of pharma is to be able to continuously. And this start, you know,
    now I start thinking about agile software development and how other industries
    have sort of changed dramatically from these long lengthy timelines and processes
    into much faster cycles.
  topic: Business Strategy/Agile Transformation
- impact_reason: A key takeaway summarizing AI's role in shifting R&D investment from
    intuition to data-driven certainty.
  relevance_score: 10
  source: llm_enhanced
  text: AI is redefining early-stage drug development, enabling pharmaceutical leaders
    to make smarter investment decisions based on data, not instinct.
  topic: AI/Investment Strategy
- impact_reason: Identifies the critical bottleneck in the value chain—clinical trials—which
    must be addressed for AI-driven discovery to realize its full potential.
  relevance_score: 9
  source: llm_enhanced
  text: The clinical trial process hasn't, you can't just multiply your throughput
    by a factor of 10x, right? Unless you change some things.
  topic: Industry Bottleneck/Challenge
- impact_reason: A direct statement on the rising organizational importance and influence
    of technology departments within historically science-led organizations.
  relevance_score: 9
  source: llm_enhanced
  text: I think they're I think the role for tech functions within pharma is dramatically
    increasing.
  topic: Organizational Structure
- impact_reason: A concise summary of the convergence trend between highly regulated
    industries (like Pharma) and technology firms.
  relevance_score: 9
  source: llm_enhanced
  text: It looks a lot more like a tech company.
  topic: Industry Convergence
- impact_reason: Distinguishes AI's value as creating new possibilities (solving the
    unsolvable) rather than just incremental optimization.
  relevance_score: 9
  source: llm_enhanced
  text: It's really starting to solve problems that not just more efficiently, but
    solve problems that were unsolvable not long ago.
  topic: Technology Impact
- impact_reason: Provides a concrete example of AI solving real-world data quality
    issues (imputation) to drive strategic investment decisions.
  relevance_score: 9
  source: llm_enhanced
  text: We can enhance the data through predictive models that may even if coding
    isn't great in electronic medical records and maybe some genetic data is missing,
    it can be predicted with a fair degree of accuracy to help inform the drug development
    portfolio choices...
  topic: Technical Application
- impact_reason: Emphasizes the necessity of holistic, end-to-end value chain thinking
    for organizational design and industry survival.
  relevance_score: 9
  source: llm_enhanced
  text: We're seeing strategy have to keep the entire value chain in mind and know
    that that's the real engine that's going to decide not just the shape of these
    industries going forward, but what the shape of the organization of the organization
    looks like going forward.
  topic: Business Strategy/Organizational Design
- impact_reason: Predicts a shift toward frequent, smaller product launches driven
    by AI-enabled microsegmentation, contrasting with traditional large-scale launches.
  relevance_score: 9
  source: llm_enhanced
  text: That's going to happen to pharma as we move into this microsegmentation driven
    by AI higher throughputs and product launches within the healthcare system that
    have to be multiplied many times over and you know, the increments of product
    launches just got to got a shortened.
  topic: AI Impact/Market Strategy
- impact_reason: Shows how granular, molecular-level technological capability (AI
    in design) cascades into massive changes across the entire business value chain.
  relevance_score: 9
  source: llm_enhanced
  text: You're seeing it all across the value chain, and it's all seemingly downstream
    just from being able to really segment at a molecular level, designing each and
    every individual protein.
  topic: Technology Impact/Value Chain
- impact_reason: 'Defines a major strategic pivot in the industry: the move from mass-market
    blockbusters to precision medicine.'
  relevance_score: 9
  source: llm_enhanced
  text: Portfolio strategies in pharma are evolving fast as the industry shifts away
    from blockbuster drugs toward niche, highly targeted therapies.
  topic: Business Strategy/Market Shift
- impact_reason: Reinforces the organizational convergence theme, linking it directly
    to the adoption of data infrastructure and advanced tools.
  relevance_score: 9
  source: llm_enhanced
  text: The structure of pharma organizations is starting to look more like tech companies
    with increasing data availability and advanced modeling tools.
  topic: Organizational Change/Tech Adoption
- impact_reason: Provides a clear, actionable checklist for leaders navigating this
    industry transformation.
  relevance_score: 9
  source: llm_enhanced
  text: Success now depends on agile processes, cross-functional integration, and
    tech-savvy leadership.
  topic: Leadership/Actionable Advice
- impact_reason: Highlights the strategic risk of discovery outpacing operational/regulatory
    capacity, a key concern for scaling tech solutions.
  relevance_score: 8
  source: llm_enhanced
  text: We have to scale up the capacity. This could be an enormous, we could be sitting
    on a gold mine of many promising new future drugs and not have the ability to
    get those through to approval...
  topic: Business Challenge
- impact_reason: Identifies the core challenge in pharma—long timelines—and suggests
    that technology is enabling acceleration and increased output.
  relevance_score: 8
  source: llm_enhanced
  text: The pipelines will traditionally it's very it's very long time frame from
    molecule drug discovery all the way through to commercialization, but that may
    be shortening the volume of throughput, maybe increasing.
  topic: Industry Trends/Efficiency
- impact_reason: Highlights the breakthrough nature of current AI applications in
    fundamental scientific processes.
  relevance_score: 8
  source: llm_enhanced
  text: From protein design to synthesis, AI is solving problems once thought unsolvable.
  topic: Technology Breakthroughs
- impact_reason: Actionable insight on how AI directly supports the shift toward niche
    therapies by improving segmentation and pipeline efficiency.
  relevance_score: 8
  source: llm_enhanced
  text: AI helps identify underserved patient segments and optimize development pipelines
    with greater precision.
  topic: AI Application/Optimization
- impact_reason: 'Articulates the core strategic trade-off enabled by AI: pursuing
    hyper-niche markets vs. generalized products.'
  relevance_score: 8
  source: llm_enhanced
  text: Are you going to go after all of these tiny spaces, all of these rare and
    rarer conditions? Or are you going to make a few more generalized drugs, pick
    and choose here based on what's also going on in the organization?
  topic: Business Strategy/Investment Choices
- impact_reason: Highlights the required acceleration in time-to-market cadence.
  relevance_score: 8
  source: llm_enhanced
  text: The increments of product launches just got to got a shortened.
  topic: Product Strategy/Speed
- impact_reason: 'Crucial insight for non-technical leaders: strategic AI roles are
    now central to thought leadership, not just engineering roles.'
  relevance_score: 8
  source: llm_enhanced
  text: You don't need to be an engineer or a technical expert to be on the show.
    If you're involved in AI implementation, decision-making, or strategy within your
    company, this is your opportunity to share your insights with a global audience
    of your peers.
  topic: Leadership/AI Strategy
- impact_reason: A concise statement emphasizing the increased complexity and interconnectedness
    of modern business planning (systems thinking).
  relevance_score: 7
  source: llm_enhanced
  text: Everything needs to be considered now.
  topic: Business Strategy
- impact_reason: A simple but powerful prediction about increased operational capacity
    due to technological acceleration.
  relevance_score: 7
  source: llm_enhanced
  text: The volume of throughput, maybe increasing.
  topic: Efficiency/Throughput
- impact_reason: 'Directly connects thought leadership participation with the ultimate
    business goal: demonstrating AI Return on Investment (ROI).'
  relevance_score: 7
  source: llm_enhanced
  text: If you believe you can help other leaders move the needle on AI ROI, visit
    Emerge.com and fill out our thought leaders submission form.
  topic: Business Value/ROI
- impact_reason: A philosophical statement on strategic flexibility over rigid categorization.
  relevance_score: 7
  source: llm_enhanced
  text: I think that that's yet another spectrum rather than a binary that that we're
    going to see.
  topic: Strategic Thinking
- impact_reason: Links strategic choices (spectrum vs. binary) directly to capital
    allocation.
  relevance_score: 7
  source: llm_enhanced
  text: That's going to be based on investments.
  topic: Investment Strategy
- impact_reason: Indicates that the insights discussed have broad applicability across
    other highly regulated industries like financial services.
  relevance_score: 6
  source: llm_enhanced
  text: Many differences. Maybe that'll have to be another podcast in which case we'll
    have to have you back. Thanks so much for being with us this week.
  topic: Industry Comparison
- impact_reason: Self-promotional but signals the target audience and the practical
    focus of high-level AI discussions (enterprise adoption).
  relevance_score: 6
  source: llm_enhanced
  text: AI and Business is the go-to destination for enterprise leaders navigating
    real-world AI adoption.
  topic: AI Adoption/Audience Insight
source: Unknown Source
summary: '## Summary of AI and Business Podcast Episode: AI Transforming Pharmaceutical
  R&D Investment Strategy


  This episode of the AI and Business Podcast, featuring Scott Bradley, VP of AI and
  Innovation at Novartis, provided a deep dive into how Artificial Intelligence is
  fundamentally reshaping investment strategy and portfolio management within pharmaceutical
  Research and Development (R&D). The core narrative arc moved from the obsolescence
  of "gut-driven" decision-making to the necessity of data-informed strategies across
  the entire drug development value chain.


  **Key Takeaways for Technology Professionals:**


  **1. AI Revolutionizing Early-Stage Drug Discovery and Investment:**

  *   **Technical Advancement:** AI is solving previously "unsolvable" problems in
  the earliest phases of drug development, particularly in understanding the massive
  complexity of proteins. This includes identifying promising molecular targets and,
  crucially, designing and synthesizing novel proteins—a process that used to take
  months of human effort but can now take minutes or hours.

  *   **Data-Informed Strategy:** The industry is rapidly shifting from reliance on
  senior leaders'' "gut instinct" to data-driven investment choices. This shift is
  driven by the ability of AI to decode complex biological pathways with high predictability
  regarding safety and efficacy.


  **2. Strategic Shift: From Blockbuster to Niche Therapies (Indie Drugs):**

  *   **Portfolio Segmentation:** Pharma is moving away from the era of the blockbuster
  drug toward highly targeted, "indie film" therapies for smaller, narrowly defined
  patient populations (microsegmentation). AI enables the identification and precise
  targeting of these smaller groups, potentially increasing the number of viable drug
  assets in the pipeline by orders of magnitude.

  *   **Value Chain Integration:** This microsegmentation places immense pressure
  on the entire value chain, especially clinical trials, which cannot simply multiply
  throughput by 10x. Strategic portfolio decisions must now consider the capacity
  to shepherd numerous smaller assets through approval simultaneously.


  **3. Organizational Transformation and Technical Requirements:**

  *   **Pharma as Tech Company:** The structure of pharmaceutical organizations is
  beginning to resemble tech companies due to the increased availability of deep,
  nuanced patient health data and advanced predictive modeling tools. The role of
  technology functions is dramatically increasing.

  *   **Explainability and Trust:** While R&D leaders demand high levels of explainability
  ("why" the AI produced a recommendation), trust is built iteratively by validating
  AI outputs through early preclinical steps. No one is placing blind faith in the
  models yet, but successful outputs are moving through the development lifecycle.

  *   **Agility and Speed:** The future demands shorter development cycles, mirroring
  agile software development methodologies. Increased throughput and the need to launch
  many smaller products necessitate a continuous, faster pace across discovery, development,
  and commercialization.


  **4. Strategic Challenges and Future Considerations:**

  *   **Pipeline Bottleneck:** The primary challenge is scaling clinical trial capacity
  to match the accelerated pace of AI-driven discovery.

  *   **Competitive Clustering:** A key strategic concern is whether companies will
  all cluster around the same high-potential microsegments, potentially leaving other
  untreated patient populations underserved. Portfolio management must become more
  coordinated to cover the overall disease space strategically.


  **Context and Significance:**

  This conversation is vital because it illustrates a fundamental technological inflection
  point in one of the world''s most complex and highly regulated industries. The integration
  of deep technical AI (beyond generative models) into the earliest, most capital-intensive
  stages of drug development is proving to be the engine driving strategic portfolio
  reorganization, forcing pharma to adopt tech-centric operational models to realize
  the potential of personalized medicine.'
tags:
- artificial-intelligence
- investment
- generative-ai
title: Building Agile R&D Strategies Through Predictive Analytics - with Scott Bradley
  of Novartis
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 56
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 9
  prominence: 0.9
  topic: investment
- keywords:
  - generative ai
  - genai
  - chatgpt
  - gpt
  - claude
  - text generation
  - image generation
  mentions: 1
  prominence: 0.1
  topic: generative ai
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-05 15:50:27 UTC -->
